RU2009120674A - Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов - Google Patents
Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов Download PDFInfo
- Publication number
- RU2009120674A RU2009120674A RU2009120674/15A RU2009120674A RU2009120674A RU 2009120674 A RU2009120674 A RU 2009120674A RU 2009120674/15 A RU2009120674/15 A RU 2009120674/15A RU 2009120674 A RU2009120674 A RU 2009120674A RU 2009120674 A RU2009120674 A RU 2009120674A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- ylcarbonyl
- diazabicyclo
- pharmaceutically acceptable
- octane
- Prior art date
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 title 1
- 229960004373 acetylcholine Drugs 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 208000028017 Psychotic disease Diseases 0.000 claims abstract 8
- 208000010877 cognitive disease Diseases 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 8
- 201000000980 schizophrenia Diseases 0.000 claims abstract 8
- GTUIQNHJSXQMKW-OCAPTIKFSA-N [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone Chemical compound Clc1ccc(o1)C(=O)N1C[C@@H]2CNC[C@@H]2C1 GTUIQNHJSXQMKW-OCAPTIKFSA-N 0.000 claims abstract 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract 6
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract 6
- 206010012289 Dementia Diseases 0.000 claims abstract 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract 6
- 208000020186 Schizophreniform disease Diseases 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims abstract 4
- 206010027175 memory impairment Diseases 0.000 claims abstract 4
- 208000022610 schizoaffective disease Diseases 0.000 claims abstract 4
- -1 5-chlorofuran-2-ylcarbonyl Chemical group 0.000 claims abstract 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims abstract 2
- 206010039966 Senile dementia Diseases 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 201000004810 Vascular dementia Diseases 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 230000006735 deficit Effects 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 206010013932 dyslexia Diseases 0.000 claims abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемые соли. ! 2. Способ лечения возрастного ухудшения памяти, слабого нарушения когнитивных способностей, предстарческой деменции, раннего начала болезни Альцгеймера, старческой деменции, деменции типа Альцгеймера, деменции с тельцами Леви, сосудистой деменции, болезни Альцгеймера, удара, комплекса СПИД-деменция, синдрома дефицита внимания, гиперактивного расстройства с дефицитом внимания, дислексии, шизофрении, шизофреноформного расстройства, нарушения познавательной способности при шизофрении и шизоаффективного расстройства, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли. ! 3. Способ для лечения деменции типа Альцгеймера в степени от слабой до умеренной, синдрома дефицита внимания, умеренного нарушения когнитивных способностей или возрастного ухудшения памяти, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли. ! 4. Способ лечения синдрома дефицита внимания или гиперактивности, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло [3.3.0] октан или его фармацевтически приемлемой соли. ! 5. Способ лечения шизофрении, шизофреноформного расстройства, нарушения познавательной способности при шизофрении и шизоаффективного расстройства, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли. ! 6. Фармацевтическая композиция, содержащая в качестве активного ингредиента соединение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.
Claims (6)
1. Соединение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемые соли.
2. Способ лечения возрастного ухудшения памяти, слабого нарушения когнитивных способностей, предстарческой деменции, раннего начала болезни Альцгеймера, старческой деменции, деменции типа Альцгеймера, деменции с тельцами Леви, сосудистой деменции, болезни Альцгеймера, удара, комплекса СПИД-деменция, синдрома дефицита внимания, гиперактивного расстройства с дефицитом внимания, дислексии, шизофрении, шизофреноформного расстройства, нарушения познавательной способности при шизофрении и шизоаффективного расстройства, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли.
3. Способ для лечения деменции типа Альцгеймера в степени от слабой до умеренной, синдрома дефицита внимания, умеренного нарушения когнитивных способностей или возрастного ухудшения памяти, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли.
4. Способ лечения синдрома дефицита внимания или гиперактивности, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло [3.3.0] октан или его фармацевтически приемлемой соли.
5. Способ лечения шизофрении, шизофреноформного расстройства, нарушения познавательной способности при шизофрении и шизоаффективного расстройства, включающий введение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемой соли.
6. Фармацевтическая композиция, содержащая в качестве активного ингредиента соединение N-(5-хлорфуран-2-илкарбонил)-3,7-диазабицикло[3.3.0]октан или его фармацевтически приемлемую соль и один или несколько фармацевтически приемлемых разбавителя, эксципиента или инертного носителя.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85607906P | 2006-11-02 | 2006-11-02 | |
| US60/856,079 | 2006-11-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009138600/04A Division RU2517693C2 (ru) | 2006-11-02 | 2007-11-01 | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009120674A true RU2009120674A (ru) | 2010-12-10 |
| RU2448969C2 RU2448969C2 (ru) | 2012-04-27 |
Family
ID=39233054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120674/04A RU2448969C2 (ru) | 2006-11-02 | 2007-11-01 | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов и фармацевтическая композиция и способы лечения с их использованием |
| RU2009138600/04A RU2517693C2 (ru) | 2006-11-02 | 2007-11-01 | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009138600/04A RU2517693C2 (ru) | 2006-11-02 | 2007-11-01 | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8114889B2 (ru) |
| EP (2) | EP2284171B1 (ru) |
| JP (2) | JP5539723B2 (ru) |
| KR (2) | KR20100124356A (ru) |
| CN (4) | CN102838605B (ru) |
| AR (2) | AR063451A1 (ru) |
| AT (2) | ATE509022T1 (ru) |
| AU (2) | AU2007317433B2 (ru) |
| BR (2) | BRPI0717930A2 (ru) |
| CA (1) | CA2663925C (ru) |
| CL (1) | CL2007003155A1 (ru) |
| CO (1) | CO6180435A2 (ru) |
| CY (1) | CY1112374T1 (ru) |
| DK (1) | DK2094703T3 (ru) |
| ES (2) | ES2395157T3 (ru) |
| HR (1) | HRP20110570T1 (ru) |
| IL (2) | IL197618A (ru) |
| MX (1) | MX2009004801A (ru) |
| MY (2) | MY156730A (ru) |
| NO (1) | NO20091251L (ru) |
| NZ (2) | NZ575557A (ru) |
| PE (2) | PE20081441A1 (ru) |
| PL (1) | PL2094703T3 (ru) |
| PT (1) | PT2094703E (ru) |
| RS (1) | RS51834B (ru) |
| RU (2) | RU2448969C2 (ru) |
| SA (1) | SA07280584B1 (ru) |
| SI (1) | SI2094703T1 (ru) |
| TW (3) | TWI404532B (ru) |
| UA (2) | UA106718C2 (ru) |
| UY (1) | UY30686A1 (ru) |
| WO (1) | WO2008057938A1 (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404532B (zh) * | 2006-11-02 | 2013-08-11 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| JP2011513421A (ja) * | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2009113950A1 (en) * | 2008-03-10 | 2009-09-17 | Astrazeneca Ab | Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist |
| ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| CN102143963A (zh) * | 2008-09-05 | 2011-08-03 | 塔加西普特公司 | 二氮杂双环辛烷的酰胺及其应用 |
| WO2010028011A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| PL2899191T3 (pl) | 2009-04-30 | 2018-01-31 | Glaxo Group Ltd | Indazole podstawione oksazolem jako inhibitory kinazy PI3 |
| RU2417082C2 (ru) * | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| WO2011061751A1 (en) | 2009-11-18 | 2011-05-26 | Suven Life Sciences Limited | BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS |
| MX2012006909A (es) | 2009-12-29 | 2012-07-10 | Suven Life Sciences Ltd | LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA. |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| BR112017008097B1 (pt) | 2014-10-20 | 2023-03-28 | Oyster Point Pharma, Inc | Método para tratar condições oculares |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| JP6845230B2 (ja) * | 2015-09-24 | 2021-03-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| EP3353176B1 (en) | 2015-09-24 | 2022-01-19 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| DK3439661T3 (da) | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
| CN110392679B (zh) | 2017-03-16 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 可用作双重atx/ca抑制剂的杂环化合物 |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| SMT201900517T1 (it) | 2017-03-20 | 2019-11-13 | Forma Therapeutics Inc | Composizioni di pirrolopirrolo come attivatori di piruvato chinasi (pkr) |
| CN113226356B (zh) | 2018-09-19 | 2025-03-04 | 诺沃挪第克健康护理股份公司 | 活化丙酮酸激酶r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
| US5854239A (en) * | 1993-12-29 | 1998-12-29 | Pfizer Inc. | Diazabicyclic neuokinin antagonists |
| US5457121A (en) | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| US6815438B2 (en) * | 1999-12-14 | 2004-11-09 | Neurosearch A/S | Heteroaryl-diazabicycloalkanes |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| JP2004529113A (ja) | 2001-03-07 | 2004-09-24 | ファイザー・プロダクツ・インク | ケモカイン受容体活性のモジュレーター |
| DK1406900T3 (da) * | 2001-07-06 | 2007-01-29 | Neurosearch As | Hidtil ukendte forbindelser, fremstilling og anvendelse deraf |
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| CN1317280C (zh) * | 2003-02-27 | 2007-05-23 | 神经研究公司 | 新的二氮杂双环芳基衍生物 |
| NZ540998A (en) * | 2003-02-27 | 2008-06-30 | Neurosearch As | Novel diazabicyclic aryl derivatives |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| ATE382623T1 (de) * | 2004-06-09 | 2008-01-15 | Hoffmann La Roche | Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln |
| US7226931B2 (en) | 2004-07-22 | 2007-06-05 | Cumbre Pharmaceuticals Inc. | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions |
| AU2006247482A1 (en) * | 2005-05-13 | 2006-11-23 | Lexicon Pharmaceuticals, Inc. | Multicyclic compounds and methods of their use |
| TWI404532B (zh) * | 2006-11-02 | 2013-08-11 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
-
2007
- 2007-10-19 TW TW099135628A patent/TWI404532B/zh not_active IP Right Cessation
- 2007-10-19 TW TW096139391A patent/TWI405763B/zh not_active IP Right Cessation
- 2007-10-19 TW TW101139986A patent/TWI454262B/zh not_active IP Right Cessation
- 2007-10-30 SA SA07280584A patent/SA07280584B1/ar unknown
- 2007-10-31 PE PE2007001487A patent/PE20081441A1/es not_active Application Discontinuation
- 2007-10-31 PE PE2011000136A patent/PE20110671A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703155A patent/CL2007003155A1/es unknown
- 2007-11-01 RS RS20110339A patent/RS51834B/sr unknown
- 2007-11-01 JP JP2009535465A patent/JP5539723B2/ja active Active
- 2007-11-01 UA UAA200912807A patent/UA106718C2/ru unknown
- 2007-11-01 RU RU2009120674/04A patent/RU2448969C2/ru not_active IP Right Cessation
- 2007-11-01 UA UAA200905474A patent/UA98944C2/ru unknown
- 2007-11-01 RU RU2009138600/04A patent/RU2517693C2/ru not_active IP Right Cessation
- 2007-11-01 AU AU2007317433A patent/AU2007317433B2/en not_active Ceased
- 2007-11-01 MX MX2009004801A patent/MX2009004801A/es active IP Right Grant
- 2007-11-01 DK DK07863786.5T patent/DK2094703T3/da active
- 2007-11-01 PT PT07863786T patent/PT2094703E/pt unknown
- 2007-11-01 BR BRPI0717930-8A patent/BRPI0717930A2/pt not_active IP Right Cessation
- 2007-11-01 BR BRPI0722387-0A patent/BRPI0722387A2/pt not_active Application Discontinuation
- 2007-11-01 KR KR1020107025973A patent/KR20100124356A/ko not_active Abandoned
- 2007-11-01 CN CN201210291637.1A patent/CN102838605B/zh not_active Expired - Fee Related
- 2007-11-01 US US12/447,850 patent/US8114889B2/en not_active Expired - Fee Related
- 2007-11-01 CN CN2010105367790A patent/CN102020646B/zh not_active Expired - Fee Related
- 2007-11-01 NZ NZ575557A patent/NZ575557A/en not_active IP Right Cessation
- 2007-11-01 CA CA2663925A patent/CA2663925C/en not_active Expired - Fee Related
- 2007-11-01 UY UY30686A patent/UY30686A1/es not_active Application Discontinuation
- 2007-11-01 ES ES10075738T patent/ES2395157T3/es active Active
- 2007-11-01 EP EP10075738A patent/EP2284171B1/en active Active
- 2007-11-01 CN CN2007800402281A patent/CN101528745B/zh not_active Expired - Fee Related
- 2007-11-01 AR ARP070104876A patent/AR063451A1/es not_active Application Discontinuation
- 2007-11-01 WO PCT/US2007/083330 patent/WO2008057938A1/en not_active Ceased
- 2007-11-01 HR HR20110570T patent/HRP20110570T1/hr unknown
- 2007-11-01 SI SI200730628T patent/SI2094703T1/sl unknown
- 2007-11-01 AT AT07863786T patent/ATE509022T1/de active
- 2007-11-01 KR KR1020097008122A patent/KR101415705B1/ko not_active Expired - Fee Related
- 2007-11-01 NZ NZ587847A patent/NZ587847A/en not_active IP Right Cessation
- 2007-11-01 PL PL07863786T patent/PL2094703T3/pl unknown
- 2007-11-01 CN CN201210401679.6A patent/CN102942569B/zh not_active Expired - Fee Related
- 2007-11-01 MY MYPI2011004927A patent/MY156730A/en unknown
- 2007-11-01 EP EP07863786A patent/EP2094703B1/en active Active
- 2007-11-01 AT AT10075738T patent/ATE545646T1/de active
- 2007-11-01 MY MYPI20091569A patent/MY145602A/en unknown
- 2007-11-01 ES ES07863786T patent/ES2395212T3/es active Active
-
2009
- 2009-03-16 IL IL197618A patent/IL197618A/en not_active IP Right Cessation
- 2009-03-26 NO NO20091251A patent/NO20091251L/no not_active Application Discontinuation
- 2009-06-01 CO CO09056352A patent/CO6180435A2/es active IP Right Grant
-
2010
- 2010-03-15 US US12/723,790 patent/US8268860B2/en not_active Expired - Fee Related
- 2010-09-07 AU AU2010219323A patent/AU2010219323B2/en not_active Ceased
- 2010-10-31 IL IL209026A patent/IL209026A/en not_active IP Right Cessation
-
2011
- 2011-01-05 AR ARP110100026A patent/AR079840A2/es not_active Application Discontinuation
- 2011-07-20 CY CY20111100706T patent/CY1112374T1/el unknown
-
2012
- 2012-01-03 US US13/342,635 patent/US8859609B2/en active Active
- 2012-07-23 US US13/555,458 patent/US8921410B2/en active Active
- 2012-11-19 JP JP2012253103A patent/JP5739398B2/ja active Active
-
2014
- 2014-11-24 US US14/551,498 patent/US20150080576A1/en not_active Abandoned
-
2015
- 2015-10-26 US US14/922,473 patent/US9580434B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009120674A (ru) | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов | |
| ATE458736T1 (de) | Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten | |
| ATE447571T1 (de) | Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält | |
| CA3156135A1 (en) | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS | |
| GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
| UA110347C2 (ru) | Производные 6-циклоалкил-1,5-дигидропиразоло [3,4-d] пиримидин-4-ону и их применение в качестве ингибиторов pde9a | |
| EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
| TW200615266A (en) | Organic compounds | |
| WO2007040438A3 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| CA2581025A1 (en) | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | |
| RU2010140613A (ru) | Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| AU2019351124A1 (en) | Inhibitors of VAP-1 | |
| US20210198218A1 (en) | Compounds for therapeutic use | |
| KR20250130704A (ko) | 암 치료 방법 | |
| EA201071352A1 (ru) | Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств | |
| WO2006092599A3 (en) | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors | |
| WO2002070515A3 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents | |
| US20210107906A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof | |
| EP2272850A3 (en) | Process for purifying staurosporine | |
| WO2006087544A8 (en) | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151102 |